Arcus Biosciences and Gilead Sciences have reported promising Phase III results from their ARC-10 study of domvanalimab and ...

The congress is a collaboration of the European Society for Medical Oncology (ESMO), the European SocieTy for Radiotherapy ...

Around half of the pharmaceutical products launched in the USA in 2023 underperformed, and 39% overperformed, according to ...

PrognomiQ has raised $34 million in a series D round led by Seer, boosting its total funding to over $135 million. The funds ...

USA-based Acadia Pharmaceuticals has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease ...

Some of the UK’s leading academics and industry professionals have welcomed Chancellor Rachel Reeves’ £520 million ($669 ...

India’s Sun Pharma has been blocked in its efforts to launch its JAK inhibitor Leqselvi (deuruxolitinib) in the USA.

The ROS1 inhibitor market for NSCLC, valued at around $290 million in 2023 across the USA, Europe, and Japan, is set for growth with new-generation therapies targeting resistance mutations.

Teva Pharmaceutical Industries’ shares were up 4% at 7,323 shekels today reported results for the quarter ended September 30, 2024.

Syndax Pharmaceuticals has entered a $350 million royalty agreement with Royalty Pharma, granting a 13.8% royalty on US sales of Niktimvo for chronic graft-versus-host disease, ending once Royalty ...

GSK’s Arexvy has received expanded approval in Canada for preventing RSV-related lower respiratory tract disease in adults ...

UK health technology assessor the National Institute for Health and Care Excellence (NICE) issued final guidance recommending ...